[The optimization of the treatment of epilepsy with carbamazepine in puberty]
Abstract:
A study was made of the pharmacokinetics of carbamazepine (CBZ) in epileptic patients in the pubertal period. In a group of patients with fully controlled fits, the concentrations of CBZ ranged within the mean values of the therapeutic concentration. Meanwhile in a group with an incomplete therapeutic effect and without any effect, the mean dose of CBZ per kg weight was even higher than that in the group with fully controlled fits. The lack of the clinical effect in part of the patients in the pubertal period on the intake of the seemingly high total doses of CBZ is not to be regarded as a cause of refusing to take it. The dose should be raised under pharmacological control.
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...


